Patent ID: 11959919
Assignee: AROCELL AB
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 0:
1. A method of selecting an adjuvant treatment for a subject diagnosed with a cancer disease and treating the subject with the selected adjuvant treatment, the method comprising the steps of:
contacting an antibody that binds specifically to a serum form of thymidine kinase 1 (STK1) protein with a first blood serum sample taken from the subject before completion of a cancer treatment selected from the group consisting of surgery, radio therapy, chemotherapy and a combination thereof;
determining a first amount of antibody binding to the STK1 protein in the first blood serum sample;
correlating the first amount of antibody binding to a first concentration of STK1 protein in the first blood serum sample using a standard curve defining a correlation between an amount of antibody binding to recombinant human TK1 (rhTK1) and a concentration of rhTK1;
contacting the antibody with a second blood serum sample taken from the subject within one to six months after completion of the cancer treatment;
determining a second amount of antibody binding to the STK1 protein in the second blood serum sample;
correlating the second amount of antibody binding to a second concentration of STK1 protein in the second body fluid sample using the standard curve;
identifying the subject as having a high risk of future cancer relapse if the second concentration is equal to or higher than the first concentration and otherwise identifying the subject as having a low risk of future cancer relapse;
selecting an adjuvant treatment for the subject based on whether the subject is identified as having high risk or low risk of future cancer relapse; and
treating the subject with the selected adjuvant treatment.